[A20-25] Fidaxomicin (Clostridioides difficile infection) - Benefit assessment according to §35a Social Code Book V
Last updated 15.06.2020
Commission awarded on 11.03.2020 by the Federal Joint Committee (G-BA).
Immune system and infections
Children and adolescents with Clostridioides difficile infection
Mild course of disease: added benefit not proven for girls; hint of lesser benefit for boys. Severe and/or recurrent course of disease: hint of considerable added benefit.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A13-05||Fidaxomicin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)||Commission completed|